4/22/2013

Merck & Co. granted Cerecor exclusive global rights to develop and market the experimental drug MK-0657, a small molecule NMDA receptor subunit 2B antagonist for all clinical indications. Cerecor plans to develop the compound as a treatment for severe refractory depression and suicidal thoughts and behavior. The deal entitles Merck to milestone fees and royalties.

Related Summaries